文献速递核素与放射性配体治疗肿瘤 PET/CT

核医学与外照射放疗在前列腺癌中的协同应用

Nuclear Medicine and External Beam Radiation Therapy in Prostate Cancer: A Synergistic Approach.
PubMed 文献 · J Nucl Med · 2026-03-02

放射性药物治疗(RPT)联合外照射放疗(EBRT)正在成为前列腺癌治疗的有力策略,其历史可追溯至早期89Sr试验。临床与临床前证据显示该联合可增强肿瘤控制、改善疼痛缓解与生活质量,且毒性可控。PSMA PET在精准疾病定位、患者选择和治疗规划中起关键作用,PSMA靶向RPT(包括177Lu-PSMA)主要在转移性去势抵抗性前列腺癌中显示总生存获益。

要点

  • EBRT精准靶向可见肿瘤,RPT处理微观或全身性疾病,二者互补协同。
  • PSMA PET用于精准疾病定位、患者选择和治疗规划。
  • 177Lu-PSMA等PSMA靶向RPT主要在mCRPC中显示总生存获益。

核心结论

  • RPT联合EBRT可增强肿瘤控制、改善疼痛缓解与生活质量,且毒性可控。
  • PSMA PET在精准疾病定位、患者选择和治疗规划中起关键作用。
  • PSMA靶向RPT主要在转移性去势抵抗性前列腺癌中显示总生存获益。

研究设计与样本

  • 综述类文章,汇总临床与临床前证据,涵盖历史89Sr试验至现代PSMA靶向RPT。

主要发现

  • 临床与临床前证据显示联合治疗可增强肿瘤控制、改善疼痛缓解与生活质量,毒性可控。
  • PSMA靶向RPT(包括177Lu-PSMA)对PSMA表达癌细胞递送全身辐射,主要在转移性去势抵抗性前列腺癌中显示总生存获益。
  • 正在进行的试验探索同步与序贯策略,包括α发射体放射性配体,旨在改善生存。

临床怎么用

  • 利用PSMA PET进行精准疾病定位、患者选择和治疗规划,以指导RPT与EBRT联合策略。
  • 在转移性去势抵抗性前列腺癌中,PSMA靶向RPT可作为全身治疗手段与EBRT联合应用。

局限性

  • 实际挑战包括可及性、监管和剂量测定等问题仍待解决。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this combination leverages EBRT's precise targeting of visible tumors and RPT's ability to address microscopic or systemic disease. Clinical and preclinical evidence shows enhanced tumor control, improved pain relief, and improved quality of life with manageable toxicity. Advanced imaging-particularly prostate-specific membrane antigen (PSMA) PET-plays a pivotal role in precise disease mapping, patient selection, and therapeutic planning. PSMA-targeted RPT, including 177Lu-PSMA, expands the arsenal by delivering systemic radiation to PSMA-expressing cancer cells, with demonstrated overall survival benefits so far primarily in metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors and taxane therapies. Although practical challenges such as access, regulation, and dosimetry remain, ongoing trials are exploring concurrent and sequential strategies, including α-emitter radioligands, aiming to improve survival. As evidence accumulates and logistical barriers are addressed, combined RPT and EBRT is poised to become a standard, personalized treatment paradigm in prostate cancer care.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Abdel-Wahab M, Giammarile F. Nuclear Medicine and External Beam Radiation Therapy in Prostate Cancer: A Synergistic Approach. J Nucl Med. 2026. PMID: 41506803. doi:10.2967/jnumed.125.271268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。